Peroxisome proliferator-activated receptor gamma Serine 237 phosphorylation (pPPARγ (Ser237))

PPARγ Ser237 phosphorylation (often used interchangeably with Ser273 in scientific literature) is a key post-translational modification of the nuclear receptor PPARγ, which serves as a master regulator of fat cell development and insulin sensitivity. This specific modification is primarily catalyzed by the kinase CDK5 in white adipose tissue under conditions of obesity and high-fat feeding. Unlike classical receptor activation, this phosphorylation does not impair the receptor's ability to promote adipogenesis but specifically dysregulates a set of genes crucial for systemic insulin sensitivity, such as adiponectin and adipsin. In the phosphorylated state, these beneficial adipokines are downregulated, contributing to the development of insulin resistance and type 2 diabetes. Therapeutically, this modification has become a major target for the development of novel anti-diabetic agents. Traditional thiazolidinediones (TZDs), such as rosiglitazone and pioglitazone, achieve their insulin-sensitizing effects in part by blocking this phosphorylation, though they also act as full agonists which leads to side effects like weight gain and bone loss. Modern drug discovery efforts focus on identifying non-agonist ligands, such as SR1664, that selectively inhibit the CDK5-mediated phosphorylation of PPARγ. By preventing this modification without triggering full receptor agonism, these drugs aim to restore metabolic health and insulin sensitivity while avoiding the adverse effects associated with classical PPARγ activation.

Other names

Peroxisome proliferator-activated receptor gamma Serine 273 phosphorylationpPPARγ (Ser273)p-PPARγ (S237)CDK5-mediated PPARγ phosphorylationp-PPARγ (S273/S237)